Format

Send to

Choose Destination
J Neurooncol. 2009 Oct;95(1):23-28. doi: 10.1007/s11060-009-9895-3. Epub 2009 Apr 21.

Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse.

Author information

1
Department of Neurosurgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
2
Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul, 137-701, Korea.
3
Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul, 137-701, Korea. nslk@catholic.ac.kr.

Abstract

A glioblastoma multiforme xenograft was established in athymic nude mice via inoculation of glioblastoma cells that stably express luciferase (U87MG-LucNeo), and was monitored weekly using bioluminescence imaging (BLI). In the control groups, a steep rise in the signal was associated with the death of mice. As an adjuvant therapy, cetuximab (0.5 mg, two times) was intraperitoneally administered 4 weeks after nitrosourea treatment. For a salvage therapy, cetuximab (0.5 mg, two times) was intraperitoneally administered when recovery of the bioluminescence signal was detected after nitrosourea monotherapy. The antitumor effects of cetuximab adjuvant therapy were superior to those of nitrosourea monotherapy and cetuximab salvage therapy. This finding was consistent with the results from a survival comparison among nitrosourea monotherapy, adjuvant and salvage therapy with cetuximab. These results suggest that BLI could be used as a simple tool for predicting the efficacy of various anticancer treatments in mouse models of brain tumors. The administration of cetuximab as an adjuvant to the conventional chemotherapeutic agent is more efficient than salvage therapy.

PMID:
19381443
DOI:
10.1007/s11060-009-9895-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center